Pancreatic Cancer Research

ResearcherParacelsus Medical UniversityActive in the last 2 years

Konstantin Schlick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4407-7504; OpenAlex author ID A5007229434. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2018: 2 papers · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 15

  1. Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? Co-author DOI 10.21203/rs.3.rs-4461811/v1↗
  2. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-c… Co-author DOI 10.1002/cam4.6334↗
  3. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Last author DOI 10.1055/a-1548-4847↗
  4. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Co-author DOI 10.1016/j.ejca.2021.03.040↗
  5. Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.09.004↗
  6. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Co-author DOI 10.1177/15330338211042139↗
  7. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Co-author DOI 10.3390/biom11101469↗
  8. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Co-author DOI 10.1002/cam4.3233↗
  9. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. Co-author DOI 10.2144/fsoa-2020-0128↗
  10. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051154↗
  11. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Co-author DOI 10.1515/cclm-2018-0016↗
  12. Pancreatic cancer in young adults: changes, challenges, and solutions. Co-author DOI 10.2147/ott.s176700↗
  13. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm8111791↗
  14. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis. Co-author DOI 10.1007/s00508-018-1383-3↗
  15. Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. Co-author DOI 10.1371/journal.pone.0206688↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Greil · 10 shared papers, 2018–2024 · strength 1.42
  2. Lukas Weiß · 6 shared papers, 2018–2024 · strength 0.88
  3. Armin Gerger · 7 shared papers, 2018–2024 · strength 0.79
  4. Martin Pichler Pichler · 7 shared papers, 2018–2022 · strength 0.68
  5. Jakob Michael Riedl · 5 shared papers, 2020–2024 · strength 0.64
  6. Michael Stotz · 6 shared papers, 2018–2022 · strength 0.58
  7. Dominik Andreas Barth · 4 shared papers, 2020–2022 · strength 0.43
  8. Daniel Neureiter · 3 shared papers, 2019–2021 · strength 0.37
  9. Peter Kornprat · 4 shared papers, 2018–2020 · strength 0.36
  10. Alexander Egle And · 3 shared papers, 2018–2021 · strength 0.29
  11. Eva Valentina Klocker · 3 shared papers, 2019–2020 · strength 0.29
  12. Joanna Szkandera · 3 shared papers, 2018–2020 · strength 0.26
  13. Florian Moik · 2 shared papers, 2021–2022 · strength 0.23
  14. Stefan Stättner · 2 shared papers, 2019–2020 · strength 0.20
  15. Anna Lena Lembeck · 2 shared papers, 2018–2019 · strength 0.16
  16. Cihan Ay · 1 shared paper, 2022 · strength 0.12
  17. Florian Primavesi · 1 shared paper, 2019 · strength 0.10
  18. Florian Hohla · 1 shared paper, 2020 · strength 0.10
  19. Gabriel Rinnerthaler · 1 shared paper, 2020 · strength 0.10
  20. Eva Asamer · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.